Literature DB >> 28258704

Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle.

Julia Wattacheril1, Kristie L Rose2, Salisha Hill2, Christian Lanciault3, Clark R Murray4, Kay Washington3, Brandon Williams4, Wayne English4, Matthew Spann4, Ronald Clements4, Naji Abumrad4, Charles Robb Flynn4.   

Abstract

BACKGROUND: Molecular signaling events associated with the necroinflammatory changes in nonalcoholic steatohepatitis (NASH) are not well understood. AIMS: To understand the molecular basis of NASH, we evaluated reversible phosphorylation events in hepatic tissue derived from Class III obese subjects by phosphoproteomic means with the aim of highlighting key regulatory pathways that distinguish NASH from non-alcoholic fatty liver disease (also known as simple steatosis; SS). MATERIALS &
METHODS: Class III obese subjects undergoing bariatric surgery underwent liver biopsy (eight normal patients, eight with simple steatosis, and eight NASH patients). Our strategy was unbiased, comparing global differences in liver protein reversible phosphorylation events across the 24 subjects.
RESULTS: Of the 3078 phosphorylation sites assigned (2465 phosphoserine, 445 phosphothreonine, 165 phosphotyrosine), 53 were altered by a factor of 2 among cohorts, and of those, 12 were significantly increased or decreased by ANOVA (P < 0.05). DISCUSSION: Statistical analyses of canonical signaling pathways identified carbohydrate metabolism and RNA post-transcriptional modification among the most over-represented networks.
CONCLUSION: Collectively, these results raise the possibility of abnormalities in carbohydrate metabolism as an important trigger for the development of NASH, in parallel with already established abnormalities in lipid metabolism.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; pathway analysis; phosphoproteomics; phosphorylation; proteomics; simple steatosis

Year:  2017        PMID: 28258704      PMCID: PMC5583035          DOI: 10.1111/hepr.12885

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  63 in total

1.  A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Authors:  Zobair M Younossi; Ancha Baranova; Katharine Ziegler; Luca Del Giacco; Karen Schlauch; Timothy L Born; Hazem Elariny; Francesco Gorreta; Amy VanMeter; Abraham Younoszai; Janus P Ong; Zachary Goodman; Vikas Chandhoke
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

2.  Large-scale phosphorylation analysis of mouse liver.

Authors:  Judit Villén; Sean A Beausoleil; Scott A Gerber; Steven P Gygi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

3.  Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors.

Authors:  Cuiping Pan; Florian Gnad; Jesper V Olsen; Matthias Mann
Journal:  Proteomics       Date:  2008-11       Impact factor: 3.984

4.  Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.

Authors:  Wen Su; Yang Wang; Xiao Jia; Wenhan Wu; Linghai Li; Xiaodong Tian; Sha Li; Chunjiong Wang; Huamin Xu; Jiaqi Cao; Qifei Han; Shimeng Xu; Yong Chen; Yanfeng Zhong; Xiaoyan Zhang; Pingsheng Liu; Jan-Åke Gustafsson; Youfei Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-15       Impact factor: 11.205

5.  Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis.

Authors:  Michael H Miller; Shaun V Walsh; Abdel Atrih; Jeffrey T-J Huang; Michael A J Ferguson; John F Dillon
Journal:  J Gastroenterol Hepatol       Date:  2014-10       Impact factor: 4.029

6.  Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis.

Authors:  Tatsuhiro Tsujimoto; Hideto Kawaratani; Toshiyuki Kitazawa; Masahito Uemura; Hiroshi Fukui
Journal:  Dig Dis Sci       Date:  2012-02-25       Impact factor: 3.199

7.  Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.

Authors:  Jesper V Olsen; Blagoy Blagoev; Florian Gnad; Boris Macek; Chanchal Kumar; Peter Mortensen; Matthias Mann
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

8.  Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron transfer dissociation (ETD) mass spectrometry.

Authors:  An Chi; Curtis Huttenhower; Lewis Y Geer; Joshua J Coon; John E P Syka; Dina L Bai; Jeffrey Shabanowitz; Daniel J Burke; Olga G Troyanskaya; Donald F Hunt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Enrichment of phosphopeptides by Fe3+-immobilized magnetic nanoparticles for phosphoproteome analysis of the plasma membrane of mouse liver.

Authors:  Feng Tan; Yangjun Zhang; Wei Mi; Jinglan Wang; Junying Wei; Yun Cai; Xiaohong Qian
Journal:  J Proteome Res       Date:  2008-02-12       Impact factor: 4.466

View more
  3 in total

1.  Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits.

Authors:  Kwangwon Lee; Andrew Haddad; Abdullah Osme; Chunki Kim; Ahmad Borzou; Sergei Ilchenko; Daniela Allende; Srinivasan Dasarathy; Arthur McCullough; Rovshan G Sadygov; Takhar Kasumov
Journal:  Mol Cell Proteomics       Date:  2018-08-31       Impact factor: 5.911

Review 2.  Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

3.  Phosphoproteome profiling of mouse liver during normal aging.

Authors:  Jiang-Feng Liu; Yue Wu; Ye-Hong Yang; Song-Feng Wu; Shu Liu; Ping Xu; Jun-Tao Yang
Journal:  Proteome Sci       Date:  2022-08-05       Impact factor: 2.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.